Eli Lilly to Acquire Calytrix Bio for $1.5B in Blood Cancer Bet
Published 3 d ago1 sourceEvidence: Reported
Johnson & Johnson announced a $2.2 billion acquisition of biotech firm Ollin Biosciences. Shares initially rose but then turned negative, suggesting investor skepticism about deal value or integration risks. The move signals continued M&A activity in the pharma sector, but the market reaction indicates mixed sentiment.
AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works
Published 3 d ago1 sourceEvidence: Reported
Published 2 d ago3 sourcesEvidence: Reported
Published 5 h ago2 sourcesEvidence: Reported
Published 2 d ago2 sourcesEvidence: Reported
Published 15 h ago1 sourceEvidence: Reported
Published 8 h ago2 sourcesEvidence: Unknown
Published 22 h ago2 sourcesEvidence: Reported
Published 3 d ago2 sourcesEvidence: Reported